Financial Contrast: Anebulo Pharmaceuticals (NASDAQ:ANEB) vs. IO Biotech (NASDAQ:IOBT)

IO Biotech (NASDAQ:IOBT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Valuation & Earnings

This table compares IO Biotech and Anebulo Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08 million	($1.87)	-0.63
Anebulo Pharmaceuticals	N/A	N/A	-$11.73 million	($0.37)	-7.38

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IO Biotech has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.09, suggesting that its share price is 209% less volatile than the S&P 500.

Institutional & Insider Ownership

54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by company insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares IO Biotech and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-69.31%	-62.21%
Anebulo Pharmaceuticals	N/A	-122.98%	-109.29%

Analyst Ratings

This is a breakdown of recent ratings for IO Biotech and Anebulo Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0	0	3	0	3.00
Anebulo Pharmaceuticals	0	0	3	0	3.00

IO Biotech presently has a consensus price target of $9.67, indicating a potential upside of 726.21%. Anebulo Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 144.20%. Given IO Biotech’s higher probable upside, research analysts plainly believe IO Biotech is more favorable than Anebulo Pharmaceuticals.

Summary

IO Biotech beats Anebulo Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About IO Biotech

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.